Zhejiang Medicine Co., Ltd. (SHA:600216)
China · Delayed Price · Currency is CNY 14.72
+0.37 (2.58%)
Feb 3, 2026, 3:00 PM CST
Zhejiang Medicine Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | 1,244 | 1,161 | 429.64 | 539.57 | 1,045 | 717.4 |
Depreciation & Amortization | 656.69 | 656.69 | 724.98 | 681.6 | 587.57 | 503.81 |
Other Amortization | 69.86 | 69.86 | 2.64 | 3.75 | 0.08 | 1.12 |
Loss (Gain) From Sale of Assets | -3.09 | -3.09 | -330.16 | -3.31 | 7.95 | 23.48 |
Asset Writedown & Restructuring Costs | 96.4 | 96.4 | 15.81 | 12.8 | 46.19 | 9.85 |
Loss (Gain) From Sale of Investments | 29.6 | 29.6 | 28.59 | 56.51 | -93.54 | -150.22 |
Provision & Write-off of Bad Debts | 12.55 | 12.55 | 0.15 | -2.94 | 10.63 | -16.47 |
Other Operating Activities | 744.35 | 31.24 | -76.42 | -73.46 | 58.32 | 173.37 |
Change in Accounts Receivable | -759.44 | -759.44 | -29.42 | -161.98 | -402.19 | 76.5 |
Change in Inventory | -347.26 | -347.26 | -263.73 | -330.7 | -760.57 | -215.11 |
Change in Accounts Payable | 305.37 | 305.37 | 101.7 | -218.05 | 577.5 | 154.68 |
Change in Other Net Operating Assets | 13.69 | 13.69 | 37.47 | 33.35 | 42.24 | - |
Operating Cash Flow | 2,020 | 1,223 | 634.31 | 520.6 | 1,137 | 1,257 |
Operating Cash Flow Growth | 120.59% | 92.86% | 21.84% | -54.20% | -9.55% | 180.99% |
Capital Expenditures | -503.63 | -689.14 | -796.87 | -975.99 | -939.6 | -535.35 |
Sale of Property, Plant & Equipment | 7.67 | 200.49 | 174.48 | 7.2 | 6.97 | 27.43 |
Cash Acquisitions | - | - | - | - | -140.73 | - |
Divestitures | - | - | - | 9.12 | - | -1.6 |
Investment in Securities | 0.73 | 14.08 | 102.02 | -40.46 | 39.13 | 300.32 |
Other Investing Activities | 61.92 | 1.07 | 0.78 | 1.75 | 1.98 | 6.64 |
Investing Cash Flow | -433.31 | -473.5 | -518.59 | -971.15 | -983.69 | -237.72 |
Long-Term Debt Issued | - | 520 | 600 | 660.74 | 580 | 1,400 |
Long-Term Debt Repaid | - | -573.63 | -600.34 | -726.21 | -700.43 | -1,098 |
Net Debt Issued (Repaid) | 203.45 | -53.63 | -0.34 | -65.47 | -120.43 | 302.04 |
Issuance of Common Stock | - | - | - | 59.95 | - | - |
Repurchase of Common Stock | -29 | -29 | -1.29 | - | - | - |
Common Dividends Paid | -375.08 | -170.31 | -191.91 | -351.09 | -260.06 | -1,006 |
Other Financing Activities | -175.05 | -2.38 | 52.12 | 400.53 | 450.25 | 76.73 |
Financing Cash Flow | -375.68 | -255.32 | -141.43 | 43.91 | 69.75 | -627.47 |
Foreign Exchange Rate Adjustments | 52.55 | 11.27 | 47.64 | 76.01 | -79.84 | -42.7 |
Net Cash Flow | 1,263 | 505.75 | 21.93 | -330.62 | 142.88 | 348.82 |
Free Cash Flow | 1,516 | 534.15 | -162.56 | -455.39 | 197.05 | 721.37 |
Free Cash Flow Growth | 435.86% | - | - | - | -72.68% | - |
Free Cash Flow Margin | 16.93% | 5.70% | -2.09% | -5.61% | 2.16% | 9.84% |
Free Cash Flow Per Share | 1.58 | 0.56 | -0.17 | -0.47 | 0.20 | 0.75 |
Cash Interest Paid | 0.4 | 0.4 | 0.4 | 0.4 | - | - |
Cash Income Tax Paid | 380.71 | 352.56 | 163.05 | 344.56 | 384.41 | 307.7 |
Levered Free Cash Flow | 1,010 | 388.16 | -36.98 | -899.57 | 1,076 | 613.73 |
Unlevered Free Cash Flow | 1,024 | 404.64 | -19.27 | -878.88 | 1,100 | 642.65 |
Change in Working Capital | -830.45 | -830.45 | -160.92 | -693.92 | -525.86 | -5.6 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.